What do we know about long-term safety of GLP-1 medications?

Long-term safety data for GLP-1 medications is reassuring and growing. Liraglutide has over 10 years of post-marketing data with millions of patient-years of exposure. Semaglutide has 5+ years of clinical and real-world data. Large cardiovascular outcome trials (LEADER, SUSTAIN-6, SELECT) followed patients for 2-5 years showing sustained benefits and no new safety signals. Post-marketing surveillance continues to monitor rare events. Known long-term considerations include: sustained weight loss maintenance requires continued medication; bone density may need monitoring in older adults with significant weight loss; nutritional adequacy requires attention with long-term appetite suppression; and gallbladder disease risk persists with continued use. No increased cancer risk has emerged in long-term data, including the initially concerning thyroid signals from rodent studies. The longest data available (10+ years for liraglutide) shows the safety profile remains consistent over time. Ongoing registry studies and pharmacovigilance continue monitoring millions of users for rare or delayed adverse effects.